Publications by authors named "Martin Dyroff"

Claim this Profile
E
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Xavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, Pascal Benkert, Douglas L Arnold, Martin Dyroff

Mult Scler· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective.
Holger Scheible, Hanno Schieferstein, Ralf Schmidt, Klaus Pusecker, Ulrike Gradhand, Martin Dyroff

Xenobiotica· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.
Orestis Papasouliotis, David Mitchell, Pascal Girard, Fernando Dangond, Martin Dyroff

Clin Transl Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants.
Orestis Papasouliotis, David Mitchell, Pascal Girard, Martin Dyroff

Clin Transl Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.
Holger Scheible, Martin Dyroff, Annick Seithel-Keuth, Eleanor Harrison-Moench, Nadra Mammasse

Clin Transl Sci· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies.
Wojciech Jurczak, Simon Rule, William Townsend, David Tucker, Barbara Sarholz, Martin Dyroff

Leuk Lymphoma· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide.
Christian Lüpfert, Martin Dyroff, Oliver von Richter, Dieter Gallemann, Samer El Bawab

CPT Pharmacometrics Syst Pharmacol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic investigation of N,N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide-induced insulin depletion in the rat and RINm5F cells.
Monicah A Otieno, Nicole Bavuso, Joseph Milano, Linda Foster-Brown, Khanh-Hui Bui, Martin Dyroff

Toxicol Sci· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyridazinoquinolinetriones as NMDA glycine-site antagonists with oral antinociceptive activity in a model of neuropathic pain.
Thomas M Bare, Dean G Brown, Carey L Horchler, Megan Murphy, Rebecca A Urbanek, Martin C Dyroff

J Med Chem· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones as NMDA glycine-site antagonists.
Dean G Brown, Rebecca A Urbanek, Thomas M Bare, Frances M McLaren, Carey L Horchler, Martin C Dyroff

Bioorg Med Chem Lett· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis